<?xml version="1.0" encoding="UTF-8"?>
<p>A few monoclonal antibodies targeting the conformationally conserved envelop (E) protein Domain II or III involved in membrane fusion have shown promise with many demonstrating broad cross-activity against multiple flaviviruses including YFV [
 <xref rid="B61-vaccines-07-00179" ref-type="bibr">61</xref>,
 <xref rid="B62-vaccines-07-00179" ref-type="bibr">62</xref>,
 <xref rid="B63-vaccines-07-00179" ref-type="bibr">63</xref>,
 <xref rid="B64-vaccines-07-00179" ref-type="bibr">64</xref>,
 <xref rid="B65-vaccines-07-00179" ref-type="bibr">65</xref>,
 <xref rid="B66-vaccines-07-00179" ref-type="bibr">66</xref>]. One example of a promising, first-in-class monoclonal antibody for YF is TY014 developed by Tychan, Singapore [
 <xref rid="B67-vaccines-07-00179" ref-type="bibr">67</xref>]. TY014 was designed to neutralize multiple strains of YFV by binding to an epitope on the E protein on the surface of the virus, thereby preventing viral fusion to the host cell during viral entry [
 <xref rid="B68-vaccines-07-00179" ref-type="bibr">68</xref>]. TY014 will be evaluated in a Phase I clinical trial in healthy adult subjects to assess safety and the effect of TY014 on vaccine-associated viremia [
 <xref rid="B67-vaccines-07-00179" ref-type="bibr">67</xref>].
</p>
